- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hypertension Medication Caused Rare Case of Severe Neutropenia in Patient
In an unusual case, a patient was diagnosed with febrile neutropenia after starting benazepril, an angiotensin-converting enzyme inhibitor. The treatment is rarely associated with agranulocytosis, which is defined as severe neutropenia.
In an unusual case, a patient was diagnosed with febrile neutropenia after starting benazepril, an angiotensin-converting enzyme inhibitor. The treatment is rarely associated with agranulocytosis, which is defined as severe neutropenia.
The case was published in the American Journal of Case Reports by researchers with the Bronx Lebanon Hospital Center.
While the incidence of drug-induced agranulocytosis (DIAG) has remained stable, the condition is likely underreported, according to the authors. “The detailed pathological mechanism of DIAG is poorly understood and a causal relationship between the condition and a drug can be difficult to elicit,” they wrote.
The patient in question was admitted to the emergency department with throat pain and difficulty swallowing. The patient had a white blood cell count of 0.5 K/μL with absolute neutrophilic count of zero. Hemoglobin level and platelet count were both normal.
Once the treating physicians were able to conclude benazepril, which had been prescribed to the patient 2 months prior, was the culprit causing agranulocytosis, it was discontinued as a medication.
“This resulted in fast recovery of the white blood cell count,” the authors wrote. “The patient remained afebrile for one week and was discharged with a diagnosis of benazepril-induced agranulocytosis.
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
